Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zentalis Raises $20 Million for China Subsidiary, Zentera Therapeutics

publication date: May 20, 2020

Zentalis Pharma of the US formed a Shanghai subsidiary, Zentera Therapeutics, with $20 million of capital to develop three Zentalis oncology candidates in China. Zentalis, which recently raised $165 million in a NASDAQ IPO, develops small molecule candidates that target cancer pathways. The Zentera funding was led by Tybourne Capital Management and joined by OrbiMed Asia. Zentalis is headquartered in New York City with labs in San Diego. Anthony Sun, MD, CEO of Zentalis, will also serve as CEO of Zentera. More details....

Stock Symbol: (NSDQ: ZNTL)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital